FOR IMMEDIATE RELEASE

Media Contact:
Brigid Hasson
(202) 684-3273
BrigidHasson@Rational360.com

HSCA Applauds FDA for Releasing New Data to Enable Generic Competition

Washington, DC (June 19, 2019) – Healthcare Supply Chain Association (HSCA) President and CEO Khatereh Calleja today released the following statement applauding the U.S. Food and Drug Administration (FDA) for releasing new data to help generic drug competitors:

“The Healthcare Supply Chain Association (HSCA) and its member group purchasing organizations (GPOs) applaud FDA Commissioner Dr. Norman Sharpless for taking action to increase generic drug competition by making information regarding drug exclusivity and relative timelines more readily available to generic drug manufacturers. The enhancements to the Paragraph IV patent list will provide helpful clarity to applicants and facilitate access to lower cost medications.

“Americans rely on generic drugs to reduce costs and increase access to necessary medication, and price spikes for commonly used drugs jeopardize patient access to care. HSCA advocates for policy solutions that increase competition in the generic drug marketplace. We look forward to continuing to work with FDA to ensure a vibrant and competitive generic drug market.”

###

About the Healthcare Supply Chain Association (HSCA)
The Healthcare Supply Chain Association (HSCA) represents the nation’s leading healthcare group purchasing organizations (GPOs), which are critical cost-savings partners to America’s hospitals, homes, nursing home pharmacies, clinics, home healthcare providers and surgery centers. GPOs deliver billions in savings annually to healthcare providers, Medicare and Medicaid, and taxpayers. HSCA and its member GPOs are committed to delivering the best products at the best value to healthcare providers, to increasing competition and innovation in the market, and to being supply chain leaders in transparency and accountability. For more information, visit www.supplychainassociation.org. Follow HSCA on Twitter @HSCA.